Abstract
Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Oral
-
Adult
-
Age Factors
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / blood
-
Aspirin / administration & dosage*
-
Aspirin / adverse effects
-
Aspirin / blood
-
Cross-Over Studies
-
Disease Progression
-
Double-Blind Method
-
Fatigue / drug therapy*
-
Fatigue / immunology*
-
Fatigue / physiopathology
-
Female
-
Humans
-
Male
-
Middle Aged
-
Multiple Sclerosis / complications*
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Aspirin